Frontiers of COVID-19. Scientific and Clinical Aspects of the Novel Coronavirus 2019

Section I. History, Epidemiologic Background and Pathogenesis of Coronavirus
Chapter 01: Surfaces as a source for SARS-CoV-2 transmission
Chapter 02: Humoral immune response in SARS-CoV-2 infection & its therapeutic relevance
Chapter 03: SARS-CoV-2 Invasion and Pathogenesis of COVID-19: A Perspective of viral receptors, bradykinin and purinergic system
Chapter 04: Genetics and Biological characteristics of SARS-CoV-2
Chapter 05: COVID-19 impact on host at pathophysiological and cellular level
Chapter 06: Identification of the COVID-19 droplet deposition path and its effects on the human respiratory tract before and after the disease: A scoping novel respiratory mask design
Chapter 07: SARS-CoV-2 variants: Impact of Spike Mutations on Vaccine and Therapeutic strategies
Chapter 08: Global biologic characteristics of Variants of Concern and Variants of Interest of SARS-CoV-2
Chapter 09: Emergence of COVID-19 variants and its global impact
Section II. Clinical Observations
Chapter 10: Psychological Impacts of the COVID-19 Pandemic
Chapter 11: Spatial Epidemiology of COVID-19: Disease Risk, Prognosis, and Complications
Chapter 12: Eye disorders and neuro-ophthalmic manifestations of COVID-19
Chapter 13: Evaluation and Management of Dysphagia during the COVID-19 Pandemic
Chapter 14: Gastrointestinal Manifestations Of COVID-19, and Inflammatory Bowel Disease in the COVID-19 Era, Clinical Overview And Updated Guidelines
Chapter 15: Post COVID-19 conditions-the new challenge to mankind
Chapter 16: Association of Alpha 1 Antitrypsin deficiency with COVID-19 mortality: basis for clinical trials
Chapter 17: Social cognition approaches to understanding and changing COVID-19 preventive behaviours
Chapter 18: Neurological Complications of COVID-19
Chapter 19: The Impact of Covid-19 on Surgical Disease
Section III. Interventions and Treatments
Chapter 20: Pre-Hospital Management of COVID-19: Looking for a Future Perspective
Chapter 21: Biotechnological strategies in the intervention and treatment of COVID-19
Chapter 22: Vitamin D: A Potential Prophylactic and Therapeutic Agent against COVID-19
Section IV. Current Trends and Future Directions
Chapter 23: Rational repurposing of drugs, clinical trials candidates, and natural products for SARS-Cov-2 therapy
Chapter 24: In Silico Drug Repositioning for COVID-19: Progress and Challenges
Chapter 25: Computationally Repurposed Natural Products Targeting SARS-CoV-2 Attachment and Entry Mechanisms
Chapter 26: Different platforms, immune response modulators and challenges in SARS-CoV-2 vaccination
Chapter 27: SARS-CoV-2 vaccine against virus: mission accomplished !?
Chapter 28: COVID-19 vaccines authorized by stringent regulatory authorities and vaccine candidates expecting approval in 2021
Chapter 29: The Global Evolution of Clinical Practice During a Pandemic
Chapter 30: Anticipated Long-Term Neurobehavioral Outcomes following COVID-19
Chapter 31. The road ahead

This book aims to serve the critical interests of the global community by supplying the most current knowledge and understanding of Covid-19 epidemiology, treatment, and prognoses. There was much uncertain and contradictory information published in the first year of the novel coronavirus. The dynamics of COVID-19 have now been realized, including the type of antibodies produced in infected patients and their limited lasting endurance. This book will set the record straight on the concept of “herd immunity” and explore the current vaccine trials taking place in different countries. This comprehensive book will illuminate recent advances regarding COVID-19 and offer a possible roadmap on how to move forward.

Frontiers of COVID-19: A Pathophysiology and Epidemiology Roadmap of Novel Coronavirus Disease will be a vital and forward-looking guide for infectious disease clinicians, scientists and researchers, and students at the graduate level.
 

Sasan Adibi, PhD, Senior Member, IEEE
School of IT
Deakin University
Melbourne, Australia

A/Prof Paul Griffin
B.Sc. (Hons), MBBS, FRACP, FRCPA, FACTM
School of Medicine, University of Queensland, Queensland, Australia
Department of Infectious Diseases, Mater Health, Queensland, Australia

Melvin Sanicas, MD, MSc, FRSPH, FRSA
Senior Medical Director, Global Medical Affairs
Clover Biopharmaceuticals
Zurich, Switzerland

Maryam Rashidi, MD, PhD
Senior Postdoctoral Researcher
Immunology and Inflammation
Walter & Eliza Hall Institute of Medical Research (WEHI)
Melbourne, Australia

Francesco Lanfranchi, MD
Nuclear Medicine Unit
Department of Health Sciences (DISSAL)
University of Genoa
Genoa, Italy